Utilization of a CMV T Cell Immunity Panel in Directing Duration of Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

被引：0
|
作者：
Ray, A. [1 ]
Garner, B. [1 ]
Klein, C. [1 ]
机构：
[1] Piedmont Transplant Inst, Atlanta, GA USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2023年 / 23卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
B84
引用
收藏
页码：S793 / S793
页数：1
相关论文
共 50 条
  • [41] Ganciclovir prophylaxis in CMV high-risk renal transplant recipients.
    Kletzmayr, J
    Safar, T
    Kovarik, J
    Klauser, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A3210 - A3210
  • [42] Clinical Utility of Measuring T-Cell Immunity to CMV in Transplant Recipients
    Danziger-Isakov, L.
    Heeger, P. S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) : 987 - 988
  • [43] High Dose Valaciclovir As CMV Prophylaxis in Allogeneic Hematopoietic Stem Cell Recipients at High Risk of CMV Reactivation
    Douglas, Genevieve
    Yong, Michelle K.
    Tio, Shio Yen
    Chau, Maggie
    Sasadeusz, Joe
    Slavin, Monica
    Xie, Mingdi
    Ritchie, David
    Chee, Lynette C. Y.
    BLOOD, 2020, 136
  • [44] Utility of Cytomegalovirus T-Cell Immunity Panel to Predict CMV Infections in Lung Transplant Recipients.
    Lincoln, R. W.
    Pierce, B. J.
    Pham, C.
    Yau, S. W.
    Goodarzi, A.
    Youssef, J. G.
    Huang, H. J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 986 - 986
  • [45] CLINICAL VALIDATION OF T-TRACK® CMV TO ASSESS THE FUNCTIONALITY OF CMV-SPECIFIC CELL-MEDIATED IMMUNITY IN KIDNEY TRANSPLANT RECIPIENTS
    Banas, B.
    Steubl, D.
    Renders, L.
    Wekerle, T.
    Koch, M.
    Witzke, O.
    Muehlfeld, A.
    Sommerer, C.
    Habicht, A.
    Hugo, C.
    Huenig, T.
    Lindemann, M.
    Barabas, S.
    Deml, L.
    Wagner, R.
    Krueger, B.
    TRANSPLANT INTERNATIONAL, 2016, 29 : 20 - 20
  • [46] Valganciclovir is safe and effective for CMV prophylaxis in kidney and pancreas transplant recipients who receive antilymphocyte antibody therapy.
    Baillie, GM
    Ashcraft, E
    Taber, D
    Afzal, F
    Rogers, J
    Lin, A
    Emovon, O
    Rajagopalan, PR
    Baliga, P
    Chavin, K
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 426A - 426A
  • [47] Preemptive Therapy Versus Valganciclovir Prophylaxis in CMV R plus Kidney Transplant Recipients Receiving Antithymocyte Globulin Induction
    Couzi, L.
    Helou, S.
    Bachelet, T.
    Martin, S.
    Moreau, K.
    Morel, D.
    Lafon, M. -E.
    Garrigue, I.
    Merville, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 469 - 469
  • [48] CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor
    Schachtner, Thomas
    Stein, Maik
    Reinke, Petra
    TRANSPLANTATION, 2017, 101 (10) : E315 - E325
  • [49] Use of a CMV-Specific T Cell Immunity Panel (TCIP) to Guide Secondary Prophylaxis After CMV Infection
    Barnes, A.
    Saharia, K.
    Baddley, J.
    Prakash, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S1109 - S1110
  • [50] Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients
    Shi, Yiyun
    Lerner, Alexis Hope
    Rogers, Ralph
    Vieira, Kendra
    Merhi, Basma
    Mecadon, Krista
    Osband, Adena J.
    Bayliss, George
    Gohh, Reginald
    Morrissey, Paul
    Farmakiotis, Dimitrios
    PROGRESS IN TRANSPLANTATION, 2021, 31 (04) : 368 - 376
12345